 |
5 Diseases |  |
67 Trials |
|
67 Trials |  |
4266 News |  |
| «12...52535455565758596061626364» |
- | risperidone / Generic mfg.
Phase classification: Treatment of Severe Childhood Aggression (The TOSCA Study) (clinicaltrials.gov) - Jul 26, 2017
P4, N=168, Completed, Sponsor: Michael Aman
Phase classification: P2 --> P4
- || MK-8189 / Merck (MSD)
Trial primary completion date: An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005) (clinicaltrials.gov) - Jul 26, 2017
P2a, N=215, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P2 --> P4 Trial primary completion date: May 2018 --> Dec 2017
- | risperidone / Generic mfg.
Biomarker, New P3 trial: Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety? (clinicaltrials.gov) - Jul 24, 2017
P3, N=120, Not yet recruiting, Sponsor: Marion Trousselard
- ||| New P1 trial: Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants (clinicaltrials.gov) - Jul 18, 2017
P1, N=60, Not yet recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
- |||| Lu AF35700 / Lundbeck, Jiangsu NHWA Pharma
Trial primary completion date: DayBreak: Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia (clinicaltrials.gov) - Jul 7, 2017
P3, N=964, Recruiting, Sponsor: H. Lundbeck A/S
Trial primary completion date: May 2018 --> Dec 2017 Trial primary completion date: May 2018 --> Jan 2019
- | risperidone / Generic mfg.
Trial completion: Early Phase II Trials for Cocaine Medication Development - 1 (clinicaltrials.gov) - Jun 25, 2017
P2, N=31, Completed, Sponsor: New York State Psychiatric Institute
Trial primary completion date: May 2018 --> Jan 2019 No longer recruiting --> Completed
- risperidone / Generic mfg.
Enrollment closed, Enrollment change, Metastases: A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 16, 2017
P2, N=8, Active, not recruiting, Sponsor: ValiSeek Limited
No longer recruiting --> Completed Enrolling by invitation --> Active, not recruiting | N=20 --> 8
- | Trial primary completion date: Nicotinic Receptors and Schizophrenia (clinicaltrials.gov) - May 30, 2017
P1/2, N=0, Withdrawn, Sponsor: VA Office of Research and Development
Enrolling by invitation --> Active, not recruiting | N=20 --> 8 Trial primary completion date: Aug 2020 --> Aug 2016
- | ramelteon / Generic mfg.
Enrollment open: Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia (clinicaltrials.gov) - May 19, 2017
P4, N=120, Recruiting, Sponsor: All India Institute of Medical Sciences, Bhubaneswar
Trial primary completion date: Aug 2020 --> Aug 2016 Not yet recruiting --> Recruiting
- | New P4 trial: A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway (clinicaltrials.gov) - May 11, 2017
P4, N=300, Not yet recruiting, Sponsor: Peking University
- | risperidone / Generic mfg.
Trial completion, Enrollment change: ProjectV: Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior (clinicaltrials.gov) - May 3, 2017
P2, N=41, Completed, Sponsor: University of California, Los Angeles
Not yet recruiting --> Recruiting Recruiting --> Completed | N=52 --> 41
- ||| aripiprazole / Generic mfg., risperidone / Generic mfg., olanzapine / Generic mfg.
Trial completion, Trial primary completion date: Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone (clinicaltrials.gov) - Apr 24, 2017
P1, N=85, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed | N=52 --> 41 Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Nov 2016
- ||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Trial completion: Long-Term Study of MP-214 in Patients With Schizophrenia (clinicaltrials.gov) - Apr 7, 2017
P2/3, N=254, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Nov 2016 Active, not recruiting --> Completed
- | aripiprazole / Generic mfg., risperidone / Generic mfg.
New P4 trial: PAFIP3_3Y: Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up (clinicaltrials.gov) - Mar 24, 2017
P4, N=200, Enrolling by invitation, Sponsor: Fundaci
- |||| MK-8189 / Merck (MSD)
Enrollment open: An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005) (clinicaltrials.gov) - Mar 20, 2017
P2a, N=215, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Enrollment change: Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) (clinicaltrials.gov) - Mar 20, 2017
P=N/A, N=150, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting N=300 --> 150
- ||||||| Caplyta (lumateperone) - Intra / Cellular Therapies
Trial completion: A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment (clinicaltrials.gov) - Mar 10, 2017
P3, N=696, Completed, Sponsor: Intra-Cellular Therapies, Inc.
N=300 --> 150 Active, not recruiting --> Completed
- | ramelteon / Generic mfg.
New P4 trial: Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia (clinicaltrials.gov) - Mar 9, 2017
P4, N=120, Not yet recruiting, Sponsor: All India Institute of Medical Sciences, Bhubaneswar
- | Clinical: Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) (clinicaltrials.gov) - Feb 20, 2017
P=N/A, N=300, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Active, not recruiting --> Completed Phase classification: P4 --> P=N/A
- ||||| MK-8189 / Merck (MSD)
New P2a trial: An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005) (clinicaltrials.gov) - Feb 16, 2017
P2a, N=215, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Trial primary completion date: Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction (clinicaltrials.gov) - Feb 12, 2017
P=N/A, N=130, Active, not recruiting, Sponsor: Juntendo University
Phase classification: P4 --> P=N/A Trial primary completion date: Apr 2017 --> Jan 2017
- ||| Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
Enrollment closed: A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia (clinicaltrials.gov) - Feb 2, 2017
P4, N=51, Active, not recruiting, Sponsor: Alkermes, Inc.
Trial primary completion date: Apr 2017 --> Jan 2017 Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: Omega-3 Dietary Supplements in Schizophrenia (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=50, Completed, Sponsor: Delbert Robinson
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2015
- New trial: Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=130, Active, not recruiting, Sponsor: Juntendo University
- clozapine / Generic mfg.
Enrollment closed: CLOCS: Clozapine for Cannabis Use in Schizophrenia (clinicaltrials.gov) - Jan 6, 2017
P4, N=132, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2015 Recruiting --> Active, not recruiting
- New trial: The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=30, Recruiting, Sponsor: Dalian Seventh People's Hospital
- || Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial primary completion date: Study of the Impact of Aripiprazole (Abilify (clinicaltrials.gov) - Nov 10, 2016
P4, N=80, Recruiting, Sponsor: Deborah Yurgelun-Todd
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Dec 2017
- |||| risperidone / Generic mfg., ketamine / Generic mfg.
Trial completion: Schiz_2: Effects of Ketamine and Risperidone on Cognition (clinicaltrials.gov) - Nov 9, 2016
P4, N=87, Completed, Sponsor: University of Manchester
Trial primary completion date: Sep 2016 --> Dec 2017 Not yet recruiting --> Completed
- risperidone / Generic mfg., olanzapine / Generic mfg., quetiapine / Generic mfg.
New trial: Deprescribing Antipsychotics in Long-Term Care (clinicaltrials.gov) - Nov 8, 2016
P=N/A, N=20, Not yet recruiting, Sponsor: McMaster University
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Clinical data, Enrollment open, Trial initiation date: Striatal Connectivity and Clinical Outcome in Psychosis (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=170, Recruiting, Sponsor: Northwell Health
Not yet recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> Jul 2016
- ||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Enrollment closed: Long-Term Study of MP-214 in Patients With Schizophrenia (clinicaltrials.gov) - Oct 14, 2016
P2/3, N=254, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> Jul 2016 Recruiting --> Active, not recruiting
- | risperidone controlled-release implant (BB-0817) / Braeburn
Enrollment closed: Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant (clinicaltrials.gov) - Oct 11, 2016
P2, N=50, Active, not recruiting, Sponsor: Braeburn Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| risperidone controlled-release implant (BB-0817) / Braeburn
Enrollment closed, Enrollment change: Safety and Tolerability of Risperidone Implants (clinicaltrials.gov) - Oct 11, 2016
P3, N=145, Active, not recruiting, Sponsor: Braeburn Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=100 --> 145
- | Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
Enrollment change, Trial primary completion date: A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia (clinicaltrials.gov) - Oct 11, 2016
P4, N=50, Recruiting, Sponsor: Alkermes, Inc.
Recruiting --> Active, not recruiting | N=100 --> 145 N=90 --> 50 | Trial primary completion date: Feb 2017 --> Sep 2017
- || aripiprazole / Generic mfg., risperidone / Generic mfg., olanzapine / Generic mfg.
Trial primary completion date: Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone (clinicaltrials.gov) - Oct 11, 2016
P1, N=100, Recruiting, Sponsor: Janssen Research & Development, LLC
N=90 --> 50 | Trial primary completion date: Feb 2017 --> Sep 2017 Trial primary completion date: Sep 2016 --> Jul 2017
- New trial: The Optimal Treatment for Treatment-resistant Schizophrenia (clinicaltrials.gov) - Oct 6, 2016
P=N/A, N=150, Not yet recruiting, Sponsor: Shanghai Mental Health Center
- Arvisol (cannabidiol) / Echo Pharma
Preclinical, Trial primary completion date: CBD-IS: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study (clinicaltrials.gov) - Oct 3, 2016
P1, N=74, Recruiting, Sponsor: Central Institute of Mental Health, Mannheim
Trial primary completion date: Sep 2016 --> Jul 2017 Trial primary completion date: Oct 2016 --> Feb 2017
- | lithium carbonate ER / Generic mfg.
New P4 trial, HEOR, Cost effectiveness: Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode (clinicaltrials.gov) - Sep 28, 2016
P4, N=78, Completed, Sponsor: Federal University of Rio Grande do Sul
- ||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Trial completion: Safety and Efficacy of MP-214 in Patients With Schizophrenia (clinicaltrials.gov) - Sep 27, 2016
P2/3, N=512, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Trial primary completion date: Oct 2016 --> Feb 2017 Recruiting --> Completed
- risperidone / Generic mfg.
Enrollment open, Metastases: A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 21, 2016
P2, N=20, Enrolling by invitation, Sponsor: ValiSeek Limited
Recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- risperidone / Generic mfg.
New trial: Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral Disturbances (clinicaltrials.gov) - Sep 20, 2016
P=N/A, N=45, Not yet recruiting, Sponsor: Shalvata Mental Health Center
- aripiprazole / Generic mfg., risperidone / Generic mfg.
New trial, IO biomarker: PAFIP_TLR: Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients (clinicaltrials.gov) - Sep 13, 2016
P=N/A, N=150, Enrolling by invitation, Sponsor: Fundaci
- lithium carbonate ER / Generic mfg.
New trial, HEOR: Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=1000000, Not yet recruiting, Sponsor: University of New Mexico
- risperidone / Generic mfg.
New P2 trial, Metastases: A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 22, 2016
P2, N=20, Not yet recruiting, Sponsor: ValiSeek Limited
- risperidone / Generic mfg.
Trial completion, Enrollment change: Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers (clinicaltrials.gov) - Aug 19, 2016
P=N/A, N=11, Completed, Sponsor: Northwell Health
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed | N=25 --> 11
- Enrollment open: Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder (clinicaltrials.gov) - Aug 19, 2016
P4, N=54, Recruiting, Sponsor: Hospital de Clinicas de Porto Alegre
Active, not recruiting --> Completed | N=25 --> 11 Not yet recruiting --> Recruiting
- Enrollment change, Trial withdrawal: Nicotinic Receptors and Schizophrenia (clinicaltrials.gov) - Aug 9, 2016
P1/2, N=0, Withdrawn, Sponsor: VA Office of Research and Development
Not yet recruiting --> Recruiting N=60 --> 0 | Recruiting --> Withdrawn
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - Aug 5, 2016
P3, N=275, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
N=60 --> 0 | Recruiting --> Withdrawn Phase classification: P4 --> P3
- | risperidone / Generic mfg.
Trial completion: Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder (clinicaltrials.gov) - Aug 5, 2016
P=N/A, N=25, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Phase classification: P4 --> P3 Active, not recruiting --> Completed
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Enrollment status: PAFIP3_1Y: Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up (clinicaltrials.gov) - Aug 4, 2016
P4, N=200, Enrolling by invitation, Sponsor: Fundaci
Active, not recruiting --> Completed Recruiting --> Enrolling by invitation